Universal CAR-γδT Cell Injection in the AML Patients - Trial NCT05388305
Access comprehensive clinical trial information for NCT05388305 through Pure Global AI's free database. This phase not specified trial is sponsored by Hebei Senlang Biotechnology Inc., Ltd. and is currently Recruiting. The study focuses on AML. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hebei Senlang Biotechnology Inc., Ltd.
Timeline & Enrollment
N/A
Apr 20, 2022
May 30, 2023
Primary Outcome
Safety: Incidence and severity of adverse events
Summary
To evaluate the safety of general-purpose CAR-γδT cells in patients with refractory
 post-transplant relapsed AML.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05388305
Non-Device Trial